about
An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouseMonitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumabElectrically tunable fluidic lens imaging system for laparoscopic fluorescence-guided surgeryBreast cancer in women < or = 35 years: review of 1002 cases from a single institution.Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival.Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolinTargeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.DNA double-strand break repair: a theoretical framework and its application.Selective permeabilization of the blood-brain barrier at sites of metastasis.Locoregional treatments for triple-negative breast cancer.Clinical imaging of tumor angiogenesis.Advances in anticancer radiopharmaceuticals.Can γH2AX be used to personalise cancer treatment?PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development.Targeted radionuclide therapy in combined-modality regimens.Targeting telomerase with radiolabeled inhibitors.Internalization of Auger electron-emitting isotopes into cancer cells: a method for spatial distribution determination of equivalent source terms.Absorbed dose evaluation of Auger electron-emitting radionuclides: impact of input decay spectra on dose point kernels and S-values.Photoresists as a high spatial resolution autoradiography substrate for quantitative mapping of intra- and sub-cellular distribution of Auger electron emitting radionuclides.Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1).Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.Menadione-resistant Chinese hamster ovary cells have an increased capacity for glutathione synthesis.A ruthenium polypyridyl intercalator stalls DNA replication forks, radiosensitizes human cancer cells and is enhanced by Chk1 inhibition.Synthesis and evaluation of an (18) F-labeled derivative of F3 for targeting surface-expressed nucleolin in cancer and tumor endothelial cells.XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.MRI-guided radiotherapy of the SK-N-SH neuroblastoma xenograft model using a small animal radiation research platform.Ascites induced by interleukin-2 in the treatment of renal cancer.EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.Improved outcome of 131I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma.γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies.Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells.A high-throughput induction gene trap approach defines C4ST as a target of BMP signaling.Characterization of single α-tracks by photoresist detection and AFM analysis-focus on biomedical science and technology.
P50
Q33615020-851370E1-9F9F-48A7-A57F-3452FE530356Q33615020-9B48731E-02FD-48F4-B988-FE4191C62E90Q33740232-5C855826-CD5C-4936-902C-981DFC466C24Q33901615-A8BA0D6B-73C0-4E2B-AF81-4035A7A35D8EQ34098601-24D11920-01AC-4CD8-A31E-174BCD7D84B6Q34170410-E6FF6153-185D-49BB-AC60-41ADE0D35E20Q35087681-3D39FBC3-14AA-4C81-AF63-DC288A971FC9Q35819235-61584433-1153-473A-8EBF-31D4A0069A36Q36525188-F6CDB17D-3A39-4B01-B630-FA74D8904BA5Q36596145-DE79A027-ABB4-47FA-8E88-2CEBBC95CCCCQ37281601-EAB04D1C-9151-47B2-8ECA-FDE4108A0C52Q38046579-E4130192-6DBB-4BEC-BFE6-8F8E9E7D7C3AQ38059503-351382F5-0BA5-4A24-BD87-99896FB0B992Q38122824-7C1118AB-C5BE-487D-B811-A5F8EF70E42EQ38160911-2E323D0F-A18A-466F-A8E5-E400E7F6E4DAQ38435153-613ADA7E-E935-474C-ACDE-0D1D0207B5DBQ38662743-E4D29AA8-DD75-4F8C-8679-1F2311B5A597Q38744397-33C6B1FF-CEDB-4255-8A75-0FEBAC0AEE51Q38747744-2D21FBFF-B444-46E0-B8FF-071DAA4F0362Q39012676-72100CA1-0CFF-4A01-9C0E-4C96FD689284Q39302746-61FDE294-5DD1-402D-9795-9E662F1D9726Q39310891-0E1B133B-DA8E-4C1C-98C4-C7AB8A91B903Q39557701-046557FA-7393-428C-8801-30CDFC3D2BFDQ39740616-8B1C5EA6-5DF2-4B2F-AF3B-780FB339F2DAQ39960593-DEDE4EF8-6668-44DD-ADAD-F01079D9C841Q40053032-DDED7E6E-9BD6-41A6-B58A-C481BEE2D85CQ40092768-25859455-CF71-406A-8FCC-D3F052AA3AC4Q40223524-240AA2B6-EE08-4B45-B727-A500250D6144Q40663491-4BD69A88-2159-49BE-98FC-2949BF9E716CQ41137869-263F7299-81FA-4020-87F4-34BF1B52CB72Q41207594-1B0F3713-A1DF-4D60-92D8-47DF93E5834AQ41593876-60BC8B57-F74E-46A4-9D80-227236BF686EQ41672002-B9760739-9031-473C-B991-5FAE5A2C5A2AQ41698485-3ACD2233-A1EB-47A8-9513-AF327F7741F3Q42147355-62A00697-4A76-457F-9E92-119F8D30ADBFQ42365479-61F40DBF-DF50-4E50-B396-13DDB04C6476Q42374792-AD2364FB-8F24-465D-94AD-0E35C394423AQ42588714-ABEC6BFE-B4A9-4B2C-AB43-203EC18FF749Q44138122-DDF08220-D444-42EE-9CA6-470415F40FAAQ44154961-A6243C97-080B-4056-9F70-9E4FEC916A15
P50
description
researcher ORCID ID = 0000-0003-4672-5683
@en
wetenschapper
@nl
name
Katherine A Vallis
@ast
Katherine A Vallis
@en
Katherine A Vallis
@es
Katherine A Vallis
@nl
type
label
Katherine A Vallis
@ast
Katherine A Vallis
@en
Katherine A Vallis
@es
Katherine A Vallis
@nl
prefLabel
Katherine A Vallis
@ast
Katherine A Vallis
@en
Katherine A Vallis
@es
Katherine A Vallis
@nl
P106
P1153
6701860639
P21
P31
P496
0000-0003-4672-5683